2-methyl-3-propoxy-butane | 121637-10-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-methyl-3-propoxy-butane
• 英文别名: 2-Propyloxy-3-methyl-butan；2-Methyl-3-propoxybutane
• CAS: 121637-10-3
• 化学式: C₈H₁₈O
• 分子量: 130.23
• InChiKey: ZTOYKBCDBOCNOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-甲基-2-丁酮 、 丙醇 在 platinum(IV) oxide 盐酸 、 氢气 作用下， 生成 2-methyl-3-propoxy-butane
  参考文献：
  名称：

  1072.醚的一般合成

  摘要：

  DOI：

  10.1039/jr9630005598

文献信息

• [EN] INHIBITORS OF DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1B<br/>[FR] INHIBITEURS DE LA KINASE 1B RÉGULÉE PAR PHOSPHORYLATION DE TYROSINE À DOUBLE SPÉCIFICITÉ
  申请人：TOLREMO THERAPEUTICS AG

  公开号：WO2021064141A1

  公开（公告）日：2021-04-08

  The present invention relates to compounds of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof (I), in particular for use in the treatment, amelioration or prevention of cancer, Alzheimer, Parkinson, Down syndrome, Metabolic syndrome, Diabetes and/or osteoarthritis.

  本发明涉及式(I)的化合物，可选地以药学上可接受的盐、溶剂化合物、共晶、互变异构体、外消旋体、对映体或二对映体或其混合物的形式存在，特别用于治疗、改善或预防癌症、阿尔茨海默病、帕金森病、唐氏综合症、代谢综合征、糖尿病和/或骨关节炎。
• LIQUID COMPOSITION, RECORDING METHOD, AND RECORDED MATTER
  申请人：Gotou Hiroshi

  公开号：US20130101814A1

  公开（公告）日：2013-04-25

  A liquid composition for agglutinating particles having a negative charge which are dispersed in a dispersion liquid, the liquid composition including: an organic acid ammonium salt represented by Formula (1), and water, Formula (1) where R 1 represents a hydroxyl group, a methyl group or a hydrogen atom; and R 2 represents a hydroxyl group or a methyl group.

  一种用于凝聚分散在分散液中的带有负电荷的颗粒的液态组合物，该液态组合物包括：由式（1）表示的有机酸铵盐和水，其中，式（1）中R1表示羟基、甲基或氢原子；R2表示羟基或甲基。
• NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Bolea Christelle

  公开号：US20130252944A1

  公开（公告）日：2013-09-26

  The present invention relates to novel compounds of Formula (I), wherein M, A and Y are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR 4 ”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR 4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR 4 is involved.

  本发明涉及式(I)的新型化合物，其中M、A和Y如式(I)中所定义；发明化合物是代谢型谷氨酸受体亚型4（“mGluR4”）的调节剂，可用于治疗或预防中枢神经系统疾病以及其他受mGluR4受体调节的疾病。本发明还涉及制药组合物以及使用这种化合物制造药物的用途，以及使用这种化合物预防和治疗涉及mGluR4的疾病的用途。
• BIOACTIVE FRACTIONS AND COMPOUNDS FROM DALBERGIA SISSOO FOR THE PREVENTION OR TREATMENT OF OSTEO-HEALTH RELATED DISORDERS
  申请人：Council of Scientific & Industrial Research

  公开号：EP2705047B1

  公开（公告）日：2015-08-05
• Agents for treating neurodegenerative diseases
  申请人：Stockwell R. Brent

  公开号：US20070027164A1

  公开（公告）日：2007-02-01

  The present invention relates to compounds effective in preventing neuronal cell death, which may be used in the treatment of neurodegenerative diseases. It is based, at least in part, on the discovery that particular compounds were effective in preventing neuronal death in model systems of Huntington's Disease.